EA201992349A1 - Fgfr3-связывающие молекулы - Google Patents

Fgfr3-связывающие молекулы

Info

Publication number
EA201992349A1
EA201992349A1 EA201992349A EA201992349A EA201992349A1 EA 201992349 A1 EA201992349 A1 EA 201992349A1 EA 201992349 A EA201992349 A EA 201992349A EA 201992349 A EA201992349 A EA 201992349A EA 201992349 A1 EA201992349 A1 EA 201992349A1
Authority
EA
Eurasian Patent Office
Prior art keywords
amino acid
seq
acid sequence
conservative
acid positions
Prior art date
Application number
EA201992349A
Other languages
English (en)
Inventor
Михаэла Силакси Мелкко
Ричард Вудз
Патрисия Хенне
Барбара Зюблер
Элена Каге
Драган ГРАБУЛОВСКИ
Юлиан Бертсингер
Original Assignee
Коваген Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Коваген Аг filed Critical Коваген Аг
Publication of EA201992349A1 publication Critical patent/EA201992349A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10002—Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к полипептиду, связывающемуся с изоформами 3b и 3c рецептора 3 фактора роста фибробластов (FGFR3b и FGFR3c), где полипептид содержит аминокислотную последовательность, выбранную из группы, состоящей из (a) GVTLFVALYDYEVYGPTPMLSFHKGEKFQIL(X)(X)(X)(X)GPYWEARSL(X)TGETG(X)IPSNYVAPVDSIQ (SEQ ID NO: 1), где аминокислотные положения от (X) до (X) могут представлять собой любую аминокислотную последовательность; (b) аминокислотной последовательности, которая по меньшей мере на 95% идентична аминокислотной последовательности из (a), где при определении идентичности исключаются аминокислотные положения от (X) до (X) и при условии, что аминокислотная последовательность EVYGPTPM (SEQ ID NO: 2) в аминокислотных положениях 12-19 из SEQ ID NO: 1 является консервативной и аминокислоты P и Y в аминокислотных положениях 37 и 38 из SEQ ID NO: 1 являются консервативными; (c) GVTLFVALYDYEVMSTTALSFHKGEKF QILSQSPHGQYWEARSLTTGETG(X)IPSNYVAPVDSIQ (SEQ ID NO: 19), где аминокислотное положение (X) может представлять собой любую аминокислоту; (d) аминокислотной последовательности, которая по меньшей мере на 95% идентична аминокислотной последовательности из (c), где при определении идентичности исключается аминокислотное положение (X) и при условии, что аминокислотные последовательности EVMSTTA (SEQ ID NO: 20) в аминокислотных положениях 12-18 из SEQ ID NO: 19 и SQSPH (SEQ ID NO: 21) в аминокислотных положениях 31-35 из SEQ ID NO: 19 являются консервативными и аминокислоты Q и Y в аминокислотных положениях 37 и 38 из SEQ ID NO: 19 являются консервативными.
EA201992349A 2017-04-03 2018-04-03 Fgfr3-связывающие молекулы EA201992349A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17164482 2017-04-03
PCT/EP2018/058390 WO2018185050A1 (en) 2017-04-03 2018-04-03 Fgfr3 binding molecules

Publications (1)

Publication Number Publication Date
EA201992349A1 true EA201992349A1 (ru) 2020-02-17

Family

ID=58606015

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992349A EA201992349A1 (ru) 2017-04-03 2018-04-03 Fgfr3-связывающие молекулы

Country Status (19)

Country Link
US (2) US10722589B2 (ru)
EP (1) EP3606953B1 (ru)
JP (1) JP6840907B2 (ru)
KR (1) KR20190137831A (ru)
CN (1) CN110536904A (ru)
AU (1) AU2018247801B2 (ru)
BR (1) BR112019019666A2 (ru)
CA (1) CA3056362A1 (ru)
DK (1) DK3606953T3 (ru)
EA (1) EA201992349A1 (ru)
ES (1) ES2883377T3 (ru)
HR (1) HRP20211096T1 (ru)
HU (1) HUE054869T2 (ru)
IL (1) IL269752B (ru)
LT (1) LT3606953T (ru)
NZ (1) NZ757365A (ru)
SG (1) SG11201909252XA (ru)
SI (1) SI3606953T1 (ru)
WO (1) WO2018185050A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113039271A (zh) * 2018-10-02 2021-06-25 田边三菱制药株式会社 靶向黏结蛋白聚糖-1和成纤维细胞生长因子受体的双特异性结合剂
CN114716548A (zh) * 2021-01-05 2022-07-08 (株)爱恩德生物 抗-fgfr3抗体及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JPH02503867A (ja) 1988-04-15 1990-11-15 プロテイン　デザイン　ラブズ　インコーポレーテッド Ｉｌ‐２レセプター特異的キメラ抗体
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP0463151B1 (en) 1990-01-12 1996-06-12 Cell Genesys, Inc. Generation of xenogeneic antibodies
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE60233509D1 (de) 2001-06-20 2009-10-08 Fibron Ltd Fgfr3 blockierende antikörper, verfahren zum screening darauf und verwendungen davon
IL156495A0 (en) 2003-06-17 2004-01-04 Prochon Biotech Ltd Use of fgfr3 antagonists for treating t cell mediated diseases
CA2595398A1 (en) 2004-11-04 2006-05-11 Fibron Limited Treatment of b-cell malignancies
WO2007144893A2 (en) 2006-06-15 2007-12-21 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
EP1892248A1 (en) * 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
US8187601B2 (en) 2008-07-01 2012-05-29 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (FGFR3) binding proteins
HUE061117T2 (hu) 2009-03-25 2023-05-28 Genentech Inc Anti-FGFR3 antitestek és eljárások alkalmazásukra
NZ598351A (en) 2009-08-27 2014-08-29 Covagen Ag Il-17 binding compounds and medical uses thereof
KR20140135251A (ko) 2012-03-16 2014-11-25 코바겐 아게 항종양 활성이 있는 신규 결합 분자
EP2711016A1 (en) 2012-09-21 2014-03-26 Covagen AG Novel IL-17A binding molecules and medical uses thereof
MX2015014608A (es) * 2013-04-19 2016-03-03 Covagen Ag Novedosas moleculas de union biespecifica con actividad antitumoral.
BR112016021083A2 (pt) 2014-03-17 2017-10-03 Mitsubishi Tanabe Pharma Corp Conjugados anticorpo-fynomer

Also Published As

Publication number Publication date
BR112019019666A2 (pt) 2020-04-22
DK3606953T3 (da) 2021-08-16
IL269752B (en) 2020-03-31
WO2018185050A1 (en) 2018-10-11
AU2018247801A1 (en) 2019-09-26
US11351267B2 (en) 2022-06-07
JP2020518279A (ja) 2020-06-25
HRP20211096T1 (hr) 2021-10-15
US10722589B2 (en) 2020-07-28
KR20190137831A (ko) 2019-12-11
CN110536904A (zh) 2019-12-03
SI3606953T1 (sl) 2021-10-29
NZ757365A (en) 2022-07-01
EP3606953A1 (en) 2020-02-12
US20180280527A1 (en) 2018-10-04
SG11201909252XA (en) 2019-11-28
LT3606953T (lt) 2021-08-10
US20200345859A1 (en) 2020-11-05
ES2883377T3 (es) 2021-12-07
HUE054869T2 (hu) 2021-10-28
AU2018247801B2 (en) 2020-02-20
IL269752A (en) 2019-11-28
JP6840907B2 (ja) 2021-03-10
CA3056362A1 (en) 2018-10-11
EP3606953B1 (en) 2021-05-26

Similar Documents

Publication Publication Date Title
EA201792651A1 (ru) Аденовирусные полинуклеотиды и полипептиды
UA124343C2 (uk) Капсиди аденоасоційованого вірусу і спосіб його використання
EA201890220A1 (ru) Вакцина против rsv
FI3256579T3 (fi) Kysteiiniproteaasi
EA201790934A1 (ru) ВАРИАНТЫ ИНТЕРФЕРОНА α2b
DE602005020165D1 (de) Verfahren zur herstellung von l-arginin, l-ornithin oder l-citrullin
RU2014150224A (ru) Сконструированный белок с анкириновым повтором, связывающийся с фактором роста тромбоцитов
RS52537B (en) ACTIVIN-ACTRII ANTAGONISTS AND USES FOR ANEMIA TREATMENT
EA201792362A1 (ru) Композиции и способы для лечения целиакии спру
EA201590611A1 (ru) Новые молекулы, связывающие il-17a, и их медицинское применение
PL415888A1 (pl) Sposób wytwarzania insuliny i jej pochodnych oraz peptyd hybrydowy stosowany w tym sposobie
WO2017032856A3 (en) Compounds for inducing tissue formation and uses thereof
EA201992349A1 (ru) Fgfr3-связывающие молекулы
JP2019500414A5 (ru)
BR112016026842A2 (pt) preparação compreendendo fator viii e peptídeos de fator de von willebrand
MX2020010716A (es) Metodo para escindir de la fase solida peptidos unidos a una fase solida.
PH12017550134A1 (en) Il-37 variants
MY187334A (en) Xylanase
BR112017014737A2 (pt) formulação de peptídeos inibidores de mk2
PH12018500468A1 (en) Fusion protein
MX2020010422A (es) Alfa-amilasa maltogenica variante.
MX2017013480A (es) Composicion farmaceutica para tratar y/o prevenir el cancer.
EA202092963A1 (ru) Новый белок с противовоспалительными свойствами
MX2020007336A (es) Metodos y composiciones para modular la disfuncion de celulas endoteliales.
MX2022007237A (es) Variante del virus de la vacuna oncolitica y metodos de uso del mismo.